We are delighted to announce that additional Series B funding has been agreed, with the members of Italian Angels for Growth and Club degli Investitori having committed funds of £0.6m ($1m). This financing will be used to further advance the candidates in NeoPhore’s drug discovery pipeline.
11.10.2021
Additional Series B funding announcement
More news
16.09.2025
NeoPhore's CEO Presents at Morgan Stanley 23rd Annual Global Healthcare Conference | September 2025
NeoPhore's CEO - Michael Shih - recently presented the NeoPhore story at the Morgan Stanley Global Healthcare Conference on Monday September 8th …
16.12.2024
Neophore appoints Michael Shih as Chief Executive Officer
NeoPhore appoints Michael Shih as Chief Executive Officer Highly experienced corporate development leader with a track record of international pharma …
22.05.2024
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore …